Where clinical interpretation, study design, and older-adult applicability matter early.
I am open to selected academic and interdisciplinary collaboration on projects connected to aging, clinical complexity, biomarkers, medication safety, digital health, AI-assisted tools, and real-world older-adult care.
The best collaborations often start early, while the central question is still being shaped. Before the protocol has hardened, before the tool is too polished to question, and while there is still time to ask how it will work for the patient who is meant to benefit from it.
That early stage is where important choices are still possible. What problem is actually being addressed? Which patients are meant to benefit? What outcome would matter in practice? What assumptions are being made about cognition, frailty, medications, caregivers, workflow, or follow-up? What are the realities of the healthcare system in which the solution is meant to work?
This matters in clinical care generally, and especially in older-adult care, because even the most promising ideas rarely meet simple patients. A biomarker strategy, digital tool, AI model, intervention, or study design may look convincing in a clean setting and still need careful adjustment before it can speak clearly to multimorbidity, polypharmacy, cognitive impairment, functional decline, care dependence, and the ordinary untidiness of clinical life.
I am especially interested in work where clinical interpretation, study design, and older-adult applicability are considered early enough to shape the project, rather than late enough to become a limitation paragraph.
Possible areas of collaboration include inter-institutional academic research, protocol and study-design discussion, biomarker evidence interpretation, clinical AI and digital health review, geriatric applicability assessment, invited lectures, educational sessions, and selected advisory work where the clinical and academic fit is appropriate.
The common thread is the interpretation of evidence in real older-adult populations. A finding may be statistically persuasive, technically elegant, or biologically interesting. The next question is whether it remains clinically meaningful in the patients who will actually be affected by it.
I am interested in academic projects involving aging medicine, dementia, biomarkers, medication safety, frailty, functional outcomes, digital health, and clinical AI.
This may include multi-centre observational studies, retrospective analyses, registry-based work, systematic reviews, methodological papers, research projects, and clinically grounded collaborations.
Countries represented in past multicenter work: Australia · United States · The Netherlands · Italy · United Kingdom · Sweden · Germany · Hong Kong/China · Poland · Portugal · Japan
In older-adult research, collaboration across institutions is useful because findings need to be tested across settings rather than assumed to travel unchanged.
My perspective is shaped by clinical geriatrics, academic work in aging medicine, and long-standing interest in computational tools and AI-assisted research. It is most useful where the problem is not purely technical and not purely clinical, but somewhere in the inconvenient middle.
In that middle, small choices matter. The endpoint, the inclusion criteria, the timing of measurement, the way medication burden is handled, the validation population, the workflow assumption, or whether an output is actually actionable can all change what a study or tool can honestly claim. These choices rarely introduce themselves as major decisions. They prefer to appear later as limitations.
My training and clinical background span the United States and European Union, including undergraduate science education in the United States, ECFMG certification, USMLE Step 3 completion, medical and specialist training in Europe, and academic work in geriatrics in Poland.
This background may be useful in projects where clinical interpretation, trial design, digital health evaluation, or regulatory expectations need to be considered across different healthcare systems. The same evidence does not always travel as smoothly as the abstract suggests.
Collaboration is selective and considered individually. Projects must be compatible with clinical, academic, ethical, and institutional obligations.
Most collaboration is best suited to focused, project-based, or remote-first formats. Work can be conducted in English or Polish.
For academic collaboration, invited lectures, protocol discussion, expert consultation, or selected advisory enquiries, please use the Contact page.